CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price fell 1.7% during trading on Friday . The company traded as low as $0.28 and last traded at $0.2850. 1,251,624 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 1,710,158 shares. The stock had previously closed at $0.29.
CytoDyn Price Performance
The firm has a market capitalization of $391.45 million, a P/E ratio of -9.50 and a beta of 1.11. The stock’s fifty day simple moving average is $0.32 and its 200 day simple moving average is $0.29.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Featured Stories
- Five stocks we like better than CytoDyn
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
